Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Corp.

Division of Bayer AG

Latest From Bayer Corp.

US False Claims Act Dismissal Motions Are Executive Branch Over-Reach, Whistleblowers Say

Justice Department lacks absolute right to dismiss meritorious qui tam complaints filed by affiliates of National Healthcare Analysis Group against numerous pharmaceutical companies, whistleblowers say, taking issue with government’s “personal attacks” on their business model and research practices.

Enforcement Legal Issues

False Claims Act: US Justice Department Gives Pharma Early Christmas Present

Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.

Legal Issues Enforcement

Strong Xarelto Label Warnings Lead To Another Jury Win For Bayer And Janssen

Philadelphia jurors find that warnings of bleeding risk with Xarelto are adequate, giving companies 5-0 litigation score; sixth trial in June.

Legal Issues Drug Safety

Gottlieb Defends US FDA 2019 Budget, Device Safety Plan In House

Members of a US House Appropriations Subcommittee interrogated FDA Commissioner Scott Gottlieb on the agency's proposed 2019 budget and his newly released device safety plan. One fierce critic, Rep. Rosa DeLauro, D-RI, attacked Gottlieb's efforts to allow third-party certifiers to approve device quality manufacturing processes, and said his safety plan looked like a "high-risk" action plan.

FDA Legislation
See All